CN112334473A - 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法 - Google Patents

一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法 Download PDF

Info

Publication number
CN112334473A
CN112334473A CN201980044121.7A CN201980044121A CN112334473A CN 112334473 A CN112334473 A CN 112334473A CN 201980044121 A CN201980044121 A CN 201980044121A CN 112334473 A CN112334473 A CN 112334473A
Authority
CN
China
Prior art keywords
compound
crystal form
formula
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980044121.7A
Other languages
English (en)
Other versions
CN112334473B (zh
Inventor
杨式波
杨俊然
杜振兴
王捷
尤凌峰
冯君
贺峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Chengdu Suncadia Pharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112334473A publication Critical patent/CN112334473A/zh
Application granted granted Critical
Publication of CN112334473B publication Critical patent/CN112334473B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

式(I)杂芳基并[4,3‑c]嘧啶‑5‑胺化合物的晶型及制备方法，所述晶型具体为A、B、C、D、E、F、G、H、J、K、L、M、N、O、P晶型。这些晶型具备良好的晶型稳定性，可更好地用于临床。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201980044121.7A 2018-09-14 2019-09-12 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法 Active CN112334473B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811071438 2018-09-14
CN2018110714383 2018-09-14
PCT/CN2019/105682 WO2020052648A1 (zh) 2018-09-14 2019-09-12 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法

Publications (2)

Publication Number Publication Date
CN112334473A true CN112334473A (zh) 2021-02-05
CN112334473B CN112334473B (zh) 2022-05-27

Family

ID=69777364

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980044121.7A Active CN112334473B (zh) 2018-09-14 2019-09-12 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法

Country Status (2)

Country Link
CN (1) CN112334473B (zh)
WO (1) WO2020052648A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013140A1 (en) * 2002-08-02 2004-02-12 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
WO2018166493A1 (zh) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013140A1 (en) * 2002-08-02 2004-02-12 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
WO2018166493A1 (zh) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CN112334473B (zh) 2022-05-27
WO2020052648A1 (zh) 2020-03-19

Similar Documents

Publication Publication Date Title
US10626118B2 (en) Pyrrolopyrimidine crystal for preparing JAK inhibitor
KR20140138941A (ko) 상피 성장 인자 수용체 키나제 억제제의 염
US20110021547A1 (en) Substantially Pure and a Stable Crystalline Form of Bosentan
US20090076272A1 (en) Polymorphs of eszopiclone malate
CN111518082B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
WO2022017494A1 (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
CN108779122B (zh) 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法
US20120283274A1 (en) Crystalline forms of substituted pyrazolopyrimidines
CN112334473B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法
CN112154144B (zh) 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法
US20220162185A1 (en) Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
JP7434273B2 (ja) アゼチジン誘導体のボレート
KR100909923B1 (ko) Ｎ-(2,3-디메틸-5,6,7,8-테트라히드로푸로[2,3-ｂ]퀴놀린-4-일)-2-(2-옥소피롤리딘-1-일)아세트아미드의 다형체
RU2712226C2 (ru) Фениламинопиримидин или полиморфная форма соли фениламинопиримидина
WO2023138647A1 (zh) 一种含硫异吲哚啉类衍生物的晶型
WO2023222103A1 (zh) 一种三嗪二酮类衍生物的晶型及制备方法
US20230074179A1 (en) Polymorph of ep4 receptor antagonist, preparation method therefor and use thereof
US20220235054A1 (en) Novel maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same
CN117794913A (zh) 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用
WO2024032747A1 (zh) 三环类化合物及其医药用途
TW202313614A (zh) 咪唑啉酮衍生物的晶型
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
TW202408512A (zh) 三環類化合物及其醫藥用途
TW202340189A (zh) 含有肼基的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20231026

Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: SUNCADIA PHARMACEUTICALS Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right